publicli
fund
repositori
covid
databas
right
unrestrict
research
reus
analys
form
mean
acknowledg
origin
sourc
permiss
grant
free
elsevi
long
resourc
centr
remain
activ
microbiolog
respiratori
system
infect
http
dx
microb
includ
virus
bacteria
fungi
causal
agent
pulmonari
infect
infect
nose
sinus
throat
includ
upper
tract
infect
wherea
infect
trachea
lung
bronchial
tube
consid
lower
tract
infect
gener
upper
tract
infect
mild
natur
howev
sever
ill
high
mortal
rate
report
lower
tract
infect
estim
million
death
occur
global
due
lower
tract
infect
among
age
group
million
death
report
children
children
prone
lower
tract
viral
infect
usual
common
mode
transmiss
pulmonari
infect
contact
one
person
anoth
infect
transmit
direct
indirect
contact
individu
affect
cough
sneez
transfer
droplet
consist
microorgan
fraction
second
air
directli
deposit
mouth
nasal
mucosa
anoth
suscept
individu
exampl
mouth
droplet
peopl
suffer
cough
spread
anoth
individu
indirect
transmiss
involv
contact
suscept
individu
contamin
instrument
surfac
organ
occur
microorgan
resid
hand
infect
person
transfer
exampl
shake
hand
needl
glove
infect
person
also
transmit
infect
anoth
person
variou
type
pulmonari
infect
pneumonia
tuberculosi
pulmonari
aspergillosi
nontubercul
mycobacteri
infect
pulmonari
infect
commonli
report
develop
develop
countri
although
mani
microbiolog
test
method
avail
diagnosi
infect
variou
antimicrobi
treatment
therapi
manag
pulmonari
infect
sometim
cure
rate
infect
report
low
due
certain
limit
microbiolog
test
method
believ
slow
insensit
wherea
uncontrol
use
antibiot
creat
major
problem
antibiot
resist
recent
abil
common
pathogen
acquir
resist
wide
use
antimicrobi
therapi
increas
author
suggest
number
pathogen
exhibit
resist
one
multipl
drug
mdr
increas
gradual
current
problem
antimicrobi
resist
gramneg
gramposit
bacteria
pathogen
caus
pulmonari
infect
becom
major
threat
karchmer
report
antimicrobi
resist
particularli
preval
among
common
pathogen
associ
communityacquir
respiratori
tract
infect
includ
streptococcu
pneumonia
haemophilu
influenza
moraxella
catarrhali
streptococcu
pyogen
henc
morbid
mortal
associ
pulmonari
infect
pose
grow
challeng
clinic
practition
consid
huge
scope
applic
nanotechnolog
biomedicin
proven
nanotechnolog
play
crucial
role
manag
problem
associ
antibiot
resist
includ
multipl
drug
resist
therefor
lifethreaten
challeng
includ
pulmonari
infect
overcom
help
nanotechnolog
aim
present
chapter
discuss
global
statu
variou
pulmonari
infect
strategi
manag
describ
treatment
therapi
avail
pulmonari
infect
limit
given
multidrug
resist
major
challeng
novel
effect
altern
treatment
therapi
need
discov
addit
also
discuss
role
nanotechnolog
manag
pulmonari
infect
special
focu
differ
type
nanomateri
pneumonia
inflammatori
diseas
affect
lung
air
sac
known
alveoli
diseas
mostli
caus
virus
bacteria
fungi
worldwid
million
peopl
suffer
pneumonia
four
million
peopl
die
pneumonia
annual
common
symptom
pneumonia
includespersist
cold
fever
shake
hand
chest
pain
difficulti
breath
sever
sign
symbol
pneumonia
vomit
unconsci
convuls
bacteria
suppos
common
sourc
pneumonia
streptococcu
pneumonia
respons
infect
haemophilu
influenza
caus
infect
mycoplasma
pneumonia
also
caus
infect
popul
bacterium
like
stenotrophomona
maltophilia
also
report
caus
pneumonia
certain
virus
like
coronavirus
influenza
viru
adenoviru
respiratori
syncyti
viru
caus
pneumonia
fungal
pneumonia
rare
mostli
observ
immunocompromis
patient
tuberculosi
tb
caus
mycobacterium
tuberculosi
bacteria
usual
infect
lung
may
also
affect
part
liver
kidney
tb
observ
outsid
lung
known
extrapulmonari
tb
immunocompromis
patient
suscept
infect
mode
transmiss
diseas
air
tb
patient
speak
cough
sneez
tb
bacteria
may
spread
infect
nearbi
individu
even
person
infect
tuberculosi
may
inact
form
activ
patient
lower
immun
later
stage
life
common
sign
tb
persist
cough
sputum
week
chest
pain
loss
appetit
chill
fever
sweat
night
fatigu
weight
loss
patient
show
exist
treatment
pulmonari
infect
symptom
tb
develop
diseas
later
stage
everi
individu
becom
sick
infect
tb
bacteria
bodi
bodi
abl
fight
bacteria
peopl
infect
spread
tb
infect
other
form
infect
known
latent
tb
tb
bacteria
activ
immun
lower
case
tb
bacteria
spread
pulmonari
aspergillosi
fungal
infect
mainli
caus
aspergillu
speci
diseas
character
colon
aspergillu
spore
lung
aspergillosi
commonli
observ
peopl
affect
tb
peopl
copd
mostli
aspergillosi
caus
flavu
niger
terreu
fumigatu
commonli
found
patient
suffer
invas
aspergillosi
three
type
pulmonari
infect
allerg
bronchopulmonari
aspergillosi
abpa
chronic
pulmonari
aspergillosi
cpa
invas
pulmonari
aspergillosi
ipa
common
symptom
aspergillosi
fever
cough
breathless
chest
pain
abpa
infect
mainli
character
asthmat
patient
eosinophilia
defici
patient
gener
invas
aspergillosi
report
immunocompromis
patient
neutropenia
organ
transplant
unit
state
predomin
mycobacteria
associ
pulmonari
infect
includ
avium
complex
follow
kansasii
ntm
speci
report
ntm
pulmonari
infect
noncontagi
spread
individu
individu
howev
infect
transmit
inhal
mycobacteria
symptom
ntm
pulmonari
infect
chronic
cough
sputum
product
high
fever
weight
loss
ntm
pulmonari
infect
report
immunocompromis
patient
patient
lung
transplant
affect
cystic
fibrosi
cf
differ
treatment
avail
manag
pulmonari
infect
case
infect
durat
treatment
may
long
exampl
tb
macrolid
drug
commonli
use
manag
variou
kind
pulmonari
infect
receiv
consider
attent
antiinflammatori
immunomodulatori
action
apart
antibacteri
efficaci
min
jang
studi
vitro
vivo
efficaci
macrolid
drug
viz
azithromycin
clarithromycin
dirithromycin
erythromycin
roxithromycin
telithromycin
respiratori
viral
infect
caus
rhinoviru
respiratori
syncyti
viru
influenza
viru
result
show
signific
antivir
activ
test
pulmonari
virus
henri
et
al
propos
bacteriophag
therapi
treatment
pulmonari
infect
caus
antibioticresist
bacteria
found
pulmonari
infect
caus
antibioticresist
pseudomona
aeruginosa
safe
manag
use
variou
bacteriophag
myovirida
podovirida
famili
anoth
similar
studi
semler
et
al
demonstr
use
phage
therapi
respiratori
infect
caus
antibioticresist
burkholderia
cepacia
effect
therapi
studi
establish
b
cenocepacia
respiratori
infect
mice
use
nebul
noseonli
inhal
devic
mice
treat
differ
b
cenocepaciaspecif
phage
deliv
either
aerosol
intraperiton
inject
result
obtain
day
treatment
suggest
aerosol
phage
therapi
appear
effect
method
wherea
mice
receiv
phage
treatment
intraperiton
inject
show
signific
activ
mention
previous
pneumonia
pulmonari
infect
affect
lung
caus
variou
bacteria
eg
streptococcu
pneumonia
klebsiella
pneumonia
haemophilu
influenza
mycoplasma
pneumonia
virus
eg
adenovirus
rhinoviru
influenza
viru
respiratori
syncyti
viru
parainfluenza
viru
fungi
eg
histoplasma
capsulatum
coccidioid
immiti
blastomyc
dermatitidi
paracoccidioid
brasiliensi
sporothrix
schenckii
cryptococcu
neoforman
character
primarili
inflamm
alveoli
lung
fluid
fill
alveoli
alveoli
microscop
sac
lung
absorb
oxygen
gener
treatment
pneumonia
depend
type
sever
infect
bacteri
pneumonia
usual
treat
differ
antibiot
viz
azithromycin
erythromycin
doxycyclin
gemifloxacin
levofloxacin
cephalexin
amoxicillin
vancomycin
etc
effici
antifung
use
manag
fungal
pneumonia
includ
first
second
thirdgener
triazol
echinocandin
case
amphotericin
b
less
frequent
use
howev
viral
pneumonia
treat
rest
plenti
fluid
tb
also
one
lifethreaten
pulmonari
infect
major
public
health
problem
world
accord
survey
india
contribut
global
tb
burden
sinc
ancient
time
tb
lead
caus
morbid
mortal
last
decad
scientist
made
signific
progress
treatment
tb
regimen
optim
directli
observ
therapi
shortcours
dot
initi
implement
current
chemotherapi
use
tb
commonli
includ
combin
firstlin
drug
isoniazid
rifampin
pyrazinamid
ethambutol
month
treatment
fail
drug
resist
secondlin
drug
paraaminosalicyl
kanamycin
fluoroquinolon
capreomycin
ethionamid
cycloserin
recommend
although
drug
may
seriou
side
effect
aspergillosi
one
import
diseas
among
pulmonari
infect
caus
aspergillu
speci
report
emerg
caus
lifethreaten
infect
immunocompromis
patient
infect
prolong
neutropenia
advanc
hiv
infect
inherit
immunodefici
patient
undergon
allogen
hematopoiet
stem
cell
transplant
hsct
andor
lung
transplant
three
differ
form
aspergillosi
report
far
includ
invas
aspergillosi
chronic
saprophyt
aspergillosi
allerg
form
aspergillosi
gener
voriconazol
superior
deoxychol
amphotericin
b
damb
henc
recommend
primari
treatment
invas
aspergillosi
patient
apart
fdaapprov
compound
lipid
formul
amphotericin
b
amb
lipid
complex
ablc
lamb
amb
colloid
dispers
abcd
caspofungin
antifung
triazol
ie
itraconazol
voriconazol
posaconazol
also
recommend
similarli
chronic
aspergillosi
regular
dose
itraconazol
voriconazol
usual
prescrib
physician
wherea
treatment
allerg
form
aspergillosi
includ
combin
corticosteroid
itraconazol
among
pulmonari
infect
nontubercul
pulmonari
infect
caus
ntm
common
infect
increasingli
recogn
worldwid
differ
speci
ntm
describ
avium
complex
kansasii
abscessu
found
common
ntm
caus
infect
accord
davi
et
al
exist
therapi
avail
treatment
nontubercul
mycobacteri
pulmonari
infect
avium
show
poor
clinic
respons
rate
drug
toxic
side
effect
demonstr
use
aerosol
amikacin
standard
oral
therapi
nontubercul
mycobacteri
pulmonari
infect
significantli
improv
treatment
efficaci
without
produc
system
toxic
therefor
propos
aerosol
deliveri
amikacin
promis
adjunct
standard
therapi
pulmonari
nontubercul
mycobacteri
infect
moreov
extens
experiment
trial
requir
defin
optim
role
therapi
diseas
anoth
studi
johnson
odel
review
erad
ntm
infect
difficult
common
treatment
strategi
moreov
requir
prolong
cours
therapi
combin
drug
howev
numer
challeng
regard
treatment
ntm
pulmonari
infect
drug
manag
infect
avail
macrolid
drug
like
azithromycin
clarithromycin
effici
import
drug
therapi
mac
lung
infect
case
resist
strain
combin
therapi
rifampin
rifabutin
ethambutol
tripl
therapi
without
intraven
aminoglycosid
recommend
month
similarli
case
infect
kansasii
combin
isoniazid
rifampin
ethanbutol
mostli
recommend
month
addit
macrolid
clarithromycin
fourth
gener
fluoroquinolon
moxifloxacin
demonstr
good
vitro
activ
kansasii
may
altern
isoniazid
wherea
lung
infect
due
abscessu
difficult
treat
success
drug
therapi
alon
chemotherapi
conjunct
surgic
resect
often
recommend
toler
overal
differ
kind
medic
therapi
avail
manag
pulmonari
infect
case
pulmonari
infect
exist
treatment
therapi
show
certain
limit
briefli
discuss
number
limit
use
convent
strategi
diagnosi
treatment
patient
pulmonari
infect
consequ
unnecessari
prolong
exposur
antimicrobi
agent
advers
affect
patient
outcom
inappropri
uncontrol
use
antibiot
therapi
increas
chanc
antibiot
resist
accord
murdoch
role
microbiolog
test
method
use
diagnosi
manag
lower
respiratori
tract
infect
continu
debat
mani
limit
microbiolog
laboratori
perform
convent
diagnost
test
pulmonari
infect
cultur
base
method
current
use
slow
insensit
may
distinguish
colon
infect
may
influenc
previou
antimicrobi
use
hand
serolog
test
also
slow
poorli
sensit
therefor
mani
authorit
guidelin
manag
pulmonari
infect
communityacquir
pneumonia
adult
support
routin
comprehens
microbiolog
test
except
certain
situat
patient
sever
diseas
moreov
uncontrol
improp
use
antibiot
treatment
pulmonari
infect
lead
develop
resist
toward
antibiot
problem
antibiot
resist
predominantli
found
tb
patient
unfortun
caus
agent
tb
mani
pulmonari
infect
becom
resist
multipl
type
antibiot
loss
efficaci
antibiot
decreas
abil
fight
pulmonari
infect
vulner
patient
matter
great
concern
nanotechnolog
multidisciplinari
field
recent
emerg
look
extrem
help
manag
pulmonari
infect
nanotechnolog
base
treatment
method
drug
deliveri
strategi
help
deliv
drug
molecul
specif
site
infect
role
variou
nanomateri
diagnosi
treatment
pulmonari
infect
describ
nanotechnolog
emerg
field
scienc
deal
studi
synthesi
manipul
materi
nanomet
rang
ie
nm
order
billionth
meter
particl
nanomet
rang
chang
properti
physicochem
properti
distinct
bulk
materi
macroscop
microscop
scale
singl
atom
molecul
atom
scale
nanomateri
refer
engin
nanomet
dimens
materi
novel
properti
quantum
effect
larg
surfac
area
volum
ratio
materi
fabric
topdown
approach
bulk
materi
technolog
miniatur
bottomup
approach
assembl
occur
atom
atom
primari
larger
toward
complex
materi
synthesi
materi
nanoscal
result
magnet
mechan
chemic
electron
effect
shown
bulk
materi
nanoscal
effect
exploit
practic
everi
field
technolog
includ
commerci
applic
energi
convers
textil
cosmet
electron
water
purif
lubric
comput
much
nanobiotechnolog
studi
interact
biolog
system
nanomateri
relat
field
nanomedicin
seek
employ
nanos
materi
diagnos
treat
prevent
human
diseas
chang
physicochem
properti
critic
influenc
natur
interact
nanos
particl
come
contact
biolog
system
moreov
mani
biolog
process
immun
recognit
passag
across
biolog
barrier
also
govern
size
consider
context
variou
applic
nanotechnolog
deliveri
drug
nucleic
acidbas
therapeut
particular
diseas
site
make
promis
technolog
era
accord
buxton
deliveri
therapeut
inhal
provid
opportun
direct
transport
drug
lung
epithelium
respiratori
tract
multidisciplinari
approach
nanotechnolog
play
crucial
role
find
effici
solut
problem
variou
sector
applic
innov
nanotechnolog
field
medicin
known
nanomedicin
broad
technolog
capabl
treat
rang
diseas
use
nanoparticl
field
medicin
open
new
possibl
provid
new
method
treatment
diseas
variou
type
nanoparticl
use
medicin
treat
diseas
infecti
diseas
viral
bacteri
respiratori
tract
diseas
nanoparticl
use
treatment
diseas
includ
metal
nanoparticl
liposom
polymer
nanoparticl
dendrim
nanocomplex
nanorod
quantum
dot
nanoemuls
current
recent
studi
field
nanomedicin
chang
point
view
drug
deliveri
therapi
scientist
use
nanoparticl
carrier
drug
deliveri
therapi
fact
much
research
carri
concern
use
nanoparticl
pulmonari
diseas
howev
recent
year
scientist
may
develop
promis
nanocarri
treatment
diseas
affect
respiratori
tract
recent
studi
show
nanoparticl
pulmonari
infect
treatment
influenc
immun
system
creat
oxid
stress
caus
genotox
studi
nanoparticl
treatment
pulmonari
infecti
diseas
emerg
field
interest
treatment
respiratori
tract
condit
also
system
administr
drug
deliveri
treatment
pulmonari
diseas
varieti
metal
metal
oxid
nanoparticl
silver
gold
copper
titanium
oxid
success
exploit
pulmonari
drug
deliveri
global
million
death
report
annual
respiratori
infect
includ
least
lower
respiratori
infect
upper
respiratori
infect
develop
countri
like
china
india
iran
oman
philippin
qatar
republ
korea
saudi
arabia
thailand
unit
arab
emir
frequent
use
antibiot
lead
antibiot
resist
enabl
antibioticresist
bacteria
surviv
despit
treatment
exist
antibacteri
drug
grow
number
multidrug
resist
strain
made
imper
develop
new
antibiot
novel
approach
deliv
exist
agent
studi
carri
zhang
et
al
reveal
polyphosphoesterbas
silver
nanoparticl
enhanc
vitro
antibacteri
activ
pathogen
associ
cf
decreas
cytotox
bronchial
epitheli
cell
human
develop
novel
degrad
polyphosphoesterbas
polymer
nanoparticl
abl
carri
silver
cation
toward
treatment
lung
infect
associ
cf
format
silver
acetylid
anoth
studi
liposom
antibacteri
target
pulmonari
infect
therapi
reveal
sever
cycl
treatment
liposom
antibacteri
drug
amikacin
patient
show
continu
improv
pulmonari
function
signific
reduct
bacteri
densiti
type
studi
suggest
efficaci
antibacteri
drug
increas
administ
combin
nanoparticl
bhardwaj
cowork
use
mixtur
chemotherapeut
agentload
vesicular
system
overcom
tb
develop
ligand
append
liposom
dri
powder
inhal
accord
barash
et
al
categor
detect
specif
pattern
lung
cancer
possibl
use
gold
nanoparticl
sensor
devic
profil
unstabl
organ
compound
broza
et
al
report
use
nanomaterialsbas
sensor
identif
breathprint
earlystag
lung
cancer
pulmonari
drug
deliveri
mani
advantag
compar
unusu
drug
deliveri
strategi
especi
rapid
drug
uptak
larg
surfac
area
solut
transport
improv
drug
bioavail
well
noninvas
natur
antimicrobi
agent
enter
lung
mean
system
nanoparticl
administr
determin
potenti
harm
upon
system
exposur
drug
hand
variou
nanoparticl
exhibit
privileg
accumul
lungoth
organ
also
tri
report
intratrach
administ
antibiot
load
nanoparticl
abl
enter
alveolarcapillari
barrier
system
circul
collect
extrapulmonari
organ
contain
spleen
liver
kidney
bone
today
drug
dosag
form
therapeut
effici
improv
micron
drug
drug
micron
microspher
appropri
particl
size
administ
directli
lung
mechan
prevent
capillari
bed
lung
nanosuspens
may
ideal
approach
deliv
drug
show
depriv
solubl
pulmonari
secret
addit
due
nanoparticul
natur
homogen
size
distribut
nanosuspens
possibl
aerosol
droplet
least
one
drug
nanoparticl
present
lead
even
distribut
drug
lung
compar
microparticul
form
drug
routin
suspens
aerosol
numer
droplet
free
drug
other
fill
drug
high
amount
direct
irregular
releas
circul
drug
within
lung
nanosuspens
could
util
avail
type
nebul
aggarw
et
al
studi
antitubercular
drug
exampl
pyrazinamid
isoniazid
rifampicin
integr
variou
formul
solid
lipid
rang
formul
nebul
guinea
pig
oral
direct
pulmonari
deliveri
likewis
condit
pulmonari
aspergillosi
easili
target
appli
appropri
drug
candid
like
amphotericin
b
form
pulmonari
nanosuspens
substitut
use
stealth
liposom
numer
respiratori
diseas
treat
use
nanocarri
system
easili
transfer
airway
larg
number
pulmonari
diseas
search
includescf
genet
disord
copd
tuberculosi
pediatr
diseas
cancer
pharmacodynam
pharmacokinet
drug
exceedingli
reliant
physic
chemic
featur
influenc
type
formul
use
deliv
scale
size
compound
nanodrug
deliveri
system
ndd
transform
improv
perform
mani
drug
extent
reachabl
conserv
formul
exampl
ndd
capit
encapsul
drug
therebi
protect
degrad
target
drug
particular
cellstissuesorgan
releas
restrict
behavior
respons
precis
stimulu
increas
solubl
enhanc
epitheli
absorpt
increas
blood
circul
time
enhanc
uptak
cell
moreov
combin
ndd
concurr
detect
treat
diseas
encompass
imag
therapeut
compound
term
theranost
nanomedicin
could
play
key
role
near
futur
achiev
highli
desir
modifi
medicin
last
decad
use
design
develop
ndd
overcom
varieti
biopharmaceut
drawback
diagnosi
prevent
vaccin
diseas
treatment
intens
explor
larg
number
research
group
global
lead
enorm
number
scientif
articl
avail
intern
journal
moreov
gener
gener
ration
properti
platform
nevertheless
despit
fact
nanomedicin
began
disciplin
almost
half
centuri
ago
ndd
found
way
market
experi
could
explain
lack
econom
profit
consum
mistrust
lack
assur
poor
inform
educ
unproduct
regul
novel
gener
product
feebl
patent
protect
respiratori
system
skin
togeth
directli
contact
environ
repres
possibl
entranc
door
therapeut
compound
bodi
due
increas
frequenc
pulmonari
diseas
high
mortal
morbid
pulmonari
drug
deliveri
emerg
noninvas
smart
approach
treatment
varieti
pathogen
disord
therefor
intraven
oral
rout
diseas
manag
acquir
ever
grow
interest
system
administr
therapeut
agent
due
variou
advantag
current
research
made
enorm
stride
progress
pulmonari
deliveri
technolog
term
inhal
design
progress
nanoscal
carrier
engin
present
three
main
differ
class
devic
pulmonari
drug
deliveri
meter
dose
inhal
nebul
dri
powder
inhal
inhal
base
divers
deliveri
mechan
entail
differ
type
drug
formul
furthermor
develop
novel
biolog
activ
compound
like
protein
nucleic
acid
requir
design
innov
deliveri
technolog
bioavail
administ
drug
major
problem
pulmonari
infect
therefor
research
develop
consider
interest
pulmonari
drug
deliveri
also
focus
enhanc
bioavail
therapeut
biomolecul
high
molecular
weight
among
variou
carrier
use
drug
deliveri
system
pulmonari
infect
nanocarri
found
promis
due
signific
advantag
like
prolong
drug
releas
cellspecif
target
drug
deliveri
pulmonari
infect
caus
bacteria
fungi
virus
increas
reemerg
due
improp
use
antibiot
chang
environment
condit
convent
method
diagnosi
treatment
pulmonari
infect
limit
cultur
serolog
method
use
identif
slow
tediou
may
distinguish
colon
infect
may
influenc
previou
antimicrobi
use
treatment
context
pcr
method
use
certain
extent
rapid
identif
causal
organ
nanopcr
nanobiosensor
may
play
import
role
diagnosi
pulmonari
infect
longterm
treatment
pulmonari
infect
antibiot
inappropri
use
result
multidrug
resist
problem
problem
mainli
evidenc
tuberculosi
becom
global
problem
therefor
need
develop
altern
strategi
treatment
tuberculosi
use
nanotechnolog
diagnosi
pulmonari
infect
also
deliveri
drug
would
paramount
import
nanoparticl
particularli
biodegrad
nanoparticl
use
purpos
activ
nanoparticl
also
enhanc
use
combin
exist
antibiot
final
nanotechnolog
provid
viabl
altern
develop
longterm
strategi
tackl
problem
diagnosi
drug
deliveri
pulmonari
infect
